STATEN ISLAND, N.Y., May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2024. Highlights of the first quarter ended March 31, 2024, or in some cases shortly thereafter, include: On January 17, 2024, we announced positive comparative ...

Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2024 Or ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 82-3733567 State or other jurisdiction of (I.R.S. Employ ...

STATEN ISLAND, N.Y., April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical trial in patients with C. difficile Infection (CDI) will be presented at the 34th Congress of ESCMID Global (European Society of Clinical Microbiology and Infectious Diseases) being held in Barce ...

STATEN ISLAND, N.Y., April 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Of ...

As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. 333-278028 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACURX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial 82-3733567 (I.R.S. Employer Identification Number) 259 Liberty Avenu ...

Financial Performance - Acurx Pharmaceuticals reported a net loss of $5.1 million or $0.37 per diluted share for Q4 2023, compared to a net loss of $3.3 million or $0.28 per diluted share for Q4 2022[6]. - General and administrative expenses for Q4 2023 increased to $3.2 million from $1.8 million in Q4 2022, driven by higher professional fees and employee compensation costs[5]. - Acurx's total operating expenses for the year ended December 31, 2023, were $14.6 million, compared to $12.1 million for the previous year[15]. Research and Development - Research and development expenses for Q4 2023 were $1.9 million, up from $1.4 million in Q4 2022, primarily due to Phase 2b trial-related costs[4]. - Ibezapolstat demonstrated a clinical cure rate of 96% in the Phase 2b trial for C. difficile infection, with 100% cure in Phase 2a and 94% in Phase 2b[1]. - The company reported a 100% sustained clinical cure rate at 30 days post-treatment for patients cured at the end of treatment in the Phase 2b trial, compared to a 14.3% reinfection rate for vancomycin[1]. - The company plans to advance Ibezapolstat to Phase 3 clinical trials, with additional data expected to support its market position[1]. Regulatory and Financial Position - The company ended 2023 with cash totaling $7.5 million, down from $9.1 million at the end of 2022, but raised approximately $4.5 million through an equity offering in early 2024[3]. - Acurx submitted an Information Package to the FDA in February 2024, requesting an End of Phase 2 Meeting scheduled for April 2024[2]. - The European Medicines Agency approved Acurx's application for small to medium-sized enterprise designation, providing benefits for seeking marketing authorization in Europe[2].

As filed with the Securities and Exchange Commission on March 18, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACURX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 82-3733567 (I.R.S. Employer Identification Number) 259 Liberty Avenue Staten Island, New York 10305 (917) 533-1469 Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primar ...

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Conference Call March 18, 2024 8:00 AM ET Company Participants Robert Shawah - CFO David Luci - President and CEO Robert DeLuccia - Executive Chairman Conference Call Participants Michael Okunewithch - Maxim Group James Molloy - Alliance Global Partners Ed Arce - H.C. Wainwright Operator Greetings and welcome to the Acurx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Earnings Results and Business Update Call. At this time, all participan ...

STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2023.  Highlights of the fourth quarter ended December 31, 2023, or in some cases shortly thereafter, include: In October 2023, we ended enr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-K _____________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) ...